非小细胞肺癌EGFR-TKI耐药机制及治疗策略

发布时间：2018-05-07 18:34

本文选题：表皮生长因子受体 + 非小细胞肺癌　；参考：《肿瘤防治研究》2017年03期

【摘要】：非小细胞肺癌(non-small cell lung cancer,NSCLC)占全部肺癌的80%,而NSCLC患者中有很大一部分在确诊时已经处于晚期。因此,对于晚期NSCLC的治疗也越来越受到人们的重视。既往晚期NSCLC的标准治疗为含铂双药联合化疗,但化疗药物对改善晚期NSCLC患者的生存期方面作用十分有限。随着医学分子生物学技术的发展和肺癌分子发病机制的研究,以表皮生长因子受体(epidermal growth factor receptor,EGFR)为靶点的分子靶向治疗在NSCLC的治疗中独领风骚。其代表药物为吉非替尼和厄洛替尼,这两种EGFR-TKIs已在全世界范围内得到认可并被广泛用于晚期NSCLC的治疗,尤其是对于EGFR敏感突变者。然而,经过一段时间(中位时间为6~12月)的治疗后,大部分患者会对EGFR-TKIs产生耐药,其耐药机制主要包括原发性和获得性耐药。本文综述了近年来NSCLC耐药机制的新进展及耐药后治疗的新策略。
[Abstract]:Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer, and a large proportion of NSCLC patients are in advanced stage at the time of diagnosis. Therefore, people pay more and more attention to the treatment of advanced NSCLC. The standard treatment for advanced NSCLC is combination chemotherapy with platinum, but the effect of chemotherapy on the survival of patients with advanced NSCLC is very limited. With the development of medical molecular biological technology and the study of the molecular pathogenesis of lung cancer, epidermal growth factor receptor (EGFR) targeted molecular targeted therapy is dominant in the treatment of NSCLC. The representative drugs are Gifitinib and erlotinib, which have been recognized worldwide and widely used in the treatment of advanced NSCLC, especially for EGFR sensitive mutants. However, after a period of time (median 6 to 12 months), most patients will develop drug resistance to EGFR-TKIs, the drug resistance mechanisms mainly include primary and acquired drug resistance. This article reviews the recent advances in the mechanism of drug resistance in NSCLC and new strategies for post-drug-resistant therapy.
【作者单位】：兰州大学第一医院肿瘤内科;兰州大学第一医院放疗科;
【分类号】：R734.2

【相似文献】